Bank of Montreal Can Invests $25,000 in Gossamer Bio Inc (NASDAQ:GOSS)

Bank of Montreal Can purchased a new position in Gossamer Bio Inc (NASDAQ:GOSS) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,160 shares of the company’s stock, valued at approximately $25,000.

Separately, Creative Planning purchased a new position in shares of Gossamer Bio during the 1st quarter worth about $260,000. Hedge funds and other institutional investors own 52.76% of the company’s stock.

NASDAQ GOSS opened at $18.69 on Wednesday. Gossamer Bio Inc has a one year low of $15.59 and a one year high of $25.06. The company has a market capitalization of $1.22 billion and a P/E ratio of -0.83.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.90) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($0.27). As a group, equities analysts expect that Gossamer Bio Inc will post -2.61 EPS for the current fiscal year.

GOSS has been the topic of several recent analyst reports. Bank of America initiated coverage on shares of Gossamer Bio in a report on Tuesday, March 5th. They set a “buy” rating and a $30.00 price objective on the stock. Barclays initiated coverage on shares of Gossamer Bio in a report on Tuesday, March 5th. They set an “overweight” rating and a $27.00 price objective on the stock. Leerink Swann initiated coverage on shares of Gossamer Bio in a report on Tuesday, March 5th. They set an “outperform” rating on the stock. Svb Leerink initiated coverage on shares of Gossamer Bio in a report on Tuesday, March 5th. They set an “outperform” rating and a $30.00 price objective on the stock. Finally, Evercore ISI initiated coverage on shares of Gossamer Bio in a report on Tuesday, March 5th. They set an “outperform” rating and a $30.00 price objective on the stock. Six analysts have rated the stock with a buy rating, Gossamer Bio presently has an average rating of “Buy” and a consensus price target of $28.00.

TRADEMARK VIOLATION NOTICE: “Bank of Montreal Can Invests $25,000 in Gossamer Bio Inc (NASDAQ:GOSS)” was first reported by Markets Daily and is the property of of Markets Daily. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.themarketsdaily.com/2019/06/12/bank-of-montreal-can-invests-25000-in-gossamer-bio-inc-nasdaqgoss.html.

Gossamer Bio Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.

See Also: Yield Curve

Want to see what other hedge funds are holding GOSS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gossamer Bio Inc (NASDAQ:GOSS).

Institutional Ownership by Quarter for Gossamer Bio (NASDAQ:GOSS)

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.